Gardasil is the Last HPV Vaccine Standing
Cervarix withdrawn for the American market
GlaxoSmithKline (GSK) decided to discontinue marketing their Human Papillomavirus (HPV) vaccine, Cervarix.
Just as the Centers of Disease and Control (CDC) officials are attempting to boost vaccination rates, the Merck vaccine, Gardasil, became the only HPV product in the USA.
CDC reports HPV vaccination rates for 2015 at 40% for girls and 21% for boys, far short of a U.S. Department of Health and Human Services (HHS) goal of 80% for both boys and girls by 2020.
GSK’s last Cervarix shipments were made on August 31, 2016.
"GSK recently made the decision to stop supplying Cervarix in the U.S. due to very low market demand," the GSK spokesperson said. "With another HPV vaccine available in the U.S., patients will continue to have an option to help prevent HPV infection."
During October, a CDC committee recommended a two-dose schedule for the Gardasil vaccination.
The human papillomavirus (HPV) is the most common sexually transmitted virus in the United States. More than half of sexually active men and women are infected with HPV at some time in their lives
About 20 million Americans are currently infected, and about 6 million more get infected each year. HPV is usually spread through sexual contact. Most HPV infections don’t cause any symptoms, and go away on their own.
But HPV can cause cervical cancer in women. Cervical cancer is the 2nd leading cause of cancer deaths among women around the world. In the United States, about 10,000 women get cervical cancer every year and about 4,000 are expected to die from it.
HPV is also associated with several less common cancers, such as vaginal and vulvar cancers in women and other types of cancer in both men and women. It can also cause genital warts and warts in the throat.